Two Sigma Advisers LP Cuts Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Two Sigma Advisers LP lessened its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 32.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 156,300 shares of the biotechnology company’s stock after selling 76,700 shares during the period. Two Sigma Advisers LP owned approximately 0.73% of Enanta Pharmaceuticals worth $899,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Tower Research Capital LLC TRC grew its holdings in Enanta Pharmaceuticals by 46.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 2,274 shares during the period. AlphaQuest LLC grew its holdings in Enanta Pharmaceuticals by 16.4% during the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company’s stock worth $128,000 after acquiring an additional 3,137 shares during the period. Invesco Ltd. grew its holdings in Enanta Pharmaceuticals by 7.3% during the fourth quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company’s stock worth $268,000 after acquiring an additional 3,186 shares during the period. American Century Companies Inc. grew its holdings in Enanta Pharmaceuticals by 10.5% during the fourth quarter. American Century Companies Inc. now owns 36,962 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 3,501 shares during the period. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Enanta Pharmaceuticals during the fourth quarter worth $26,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

Enanta Pharmaceuticals Stock Performance

Enanta Pharmaceuticals stock opened at $5.97 on Monday. The firm has a market capitalization of $127.62 million, a price-to-earnings ratio of -1.21 and a beta of 0.81. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $17.24. The stock’s fifty day moving average is $5.39 and its two-hundred day moving average is $6.24.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The firm had revenue of $14.93 million during the quarter, compared to analyst estimates of $15.96 million. As a group, sell-side analysts forecast that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ENTA. JMP Securities reaffirmed a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. Wall Street Zen raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, one has given a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $17.25.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.